Health groups fear only rich will get Covid pill - RTHK
Temperature Humidity
News Archive Can search within past 12 months

Health groups fear only rich will get Covid pill

2021-10-17 HKT 22:03
Share this story facebook
  • A photo provided by Merck shows its new antiviral medication for Covid-19. Photo: AP
    A photo provided by Merck shows its new antiviral medication for Covid-19. Photo: AP
The plan to roll out Merck & Co's promising antiviral pill to treat Covid-19 risks repeating the inequities of vaccine distribution, potentially leaving the nations with the greatest need once again at the back of the queue, international health groups say.

For example, only about 5 percent of Africa’s population is immunised, creating an urgent need for therapeutics that could keep people out of hospitals. That compares with more than a 70 percent inoculation rate in most wealthy nations.

Merck on October 11 applied for U.S. emergency clearance of the first pill for Covid-19 after it cut hospital admissions and deaths by 50 percent in a large clinical trial. The medicine, made with Ridgeback Biotherapeutics, could gain authorization as soon as December.

The US drugmaker has taken the unusual pandemic step of licensing several generics of its antiviral molnupiravir before its branded version was even authorized for marketing.

But international health officials said even that is not enough for the medicine to reach many in low- and middle-income countries in large enough numbers, while noting shortcomings and red tape among global organizations that could further slow distribution.

Merck this year plans to produce 10 million treatment courses of the pill, which is taken twice a day for five days, and another 20 million next year.

In addition, its licensing deals with eight Indian drugmakers will allow cheaper generic versions for 109 low- and middle-income countries including in Africa, a move international groups acknowledge is a positive concession.

But as wealthy nations secure molnupiravir supply deals - the United States has already locked up 1.7 million courses with an option for 3.5 million more by January of 2023 at about $700 per course – concerns grow over who might be left out.

Merck said it has worked on the technology transfer needed to start generic manufacturing, in contrast to vaccine makers who continue to resist calls to waive patents or allow for generic versions to boost supplies.

But a recent report prepared for the United Nations' Access to Covid-19 Tools Accelerator programme tasked with buying Covid-19 therapeutics for poor countries cited concerns that UN agencies were not moving quickly enough to secure adequate volumes of potential new treatments ahead of time, including Merck's drug.

Medicines Patent Pool (MPP), a United Nations-backed public health organisation, has 24 companies signed up and willing to make the drug if Merck agrees to expand the licenses.

“If you're not in the license, you're relying on Merck, and it looks to us that that could mean a potential supply shortfall as well as overpricing," said Peter Maybarduk of Public Citizen, who sits on the MPP governance board. He suggested that could lead to wealthy countries outbidding poor nations for the medicine. (Reuters)